Mibavademab
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Functional Hypothalamic Amenorrhea (FHA)
Conditions
Functional Hypothalamic Amenorrhea (FHA)
Trial Timeline
Mar 31, 2026 → Dec 8, 2027
NCT ID
NCT07235917About Mibavademab
Mibavademab is a phase 2 stage product being developed by Regeneron Pharmaceuticals for Functional Hypothalamic Amenorrhea (FHA). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07235917. Target conditions include Functional Hypothalamic Amenorrhea (FHA).
What happened to similar drugs?
0 of 6 similar drugs in Functional Hypothalamic Amenorrhea (FHA) were approved
Approved (0) Terminated (1) Active (5)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07235917 | Phase 2 | Recruiting |
| NCT07220772 | Phase 3 | Recruiting |
| NCT06548100 | Phase 3 | Active |
Competing Products
20 competing products in Functional Hypothalamic Amenorrhea (FHA)